Rice Hall James & Associates’s AbbVie ABBV Stock Holding History

Rice Hall James & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.31M	Sell	5,199 -10	-0.2%	-$2.15K	0.06%	189
2026 Q1	$1.13M	Sell	5,209 -120	-2%	-$26.6K	0.06%	200
2025 Q4	$1.22M	Sell	5,329 -30	-0.6%	-$6.83K	0.07%	195
2025 Q3	$1.24M	Sell	5,359 -57	-1%	-$11.6K	0.07%	193
2025 Q2	$1.01M	Buy	5,416 +272	+5%	+$50.6K	0.05%	199
2025 Q1	$1.08M	Buy	5,144 +437	+9%	+$85K	0.06%	193
2024 Q4	$836K	Hold	4,707	–	–	0.05%	209
2024 Q3	$930K	Sell	4,707 -20	-0.4%	-$3.73K	0.05%	208
2024 Q2	$811K	Hold	4,727	–	–	0.05%	210
2024 Q1	$861K	Sell	4,727 -109	-2%	-$18.8K	0.05%	211
2023 Q4	$749K	Hold	4,836	–	–	0.04%	230
2023 Q3	$721K	Sell	4,836 -50	-1%	-$7.34K	0.05%	228
2023 Q2	$658K	Sell	4,886 -75	-2%	-$11K	0.04%	235
2023 Q1	$791K	Sell	4,961 -20	-0.4%	-$3.06K	0.04%	238
2022 Q4	$805K	Sell	4,981 -1,550	-24%	-$238K	0.05%	236
2022 Q3	$877K	Sell	6,531 -100	-2%	-$14.3K	0.05%	235
2022 Q2	$1.02M	Sell	6,631 -46	-0.7%	-$7.03K	0.05%	229
2022 Q1	$1.08M	Sell	6,677 -300	-4%	-$43.6K	0.04%	238
2021 Q4	$945K	Hold	6,977	–	–	0.03%	247
2021 Q3	$753K	Sell	6,977 -300	-4%	-$34.3K	0.03%	253
2021 Q2	$820K	Hold	7,277	–	–	0.03%	254
2021 Q1	$788K	Sell	7,277 -577	-7%	-$61.7K	0.03%	251
2020 Q4	$842K	Sell	7,854 -490	-6%	-$47.1K	0.03%	247
2020 Q3	$731K	Hold	8,344	–	–	0.03%	237
2020 Q2	$819K	Sell	8,344 -135	-2%	-$11.9K	0.04%	222
2020 Q1	$646K	Sell	8,479 -53	-0.6%	-$4.51K	0.04%	225
2019 Q4	$755K	Hold	8,532	–	–	0.03%	241
2019 Q3	$646K	Sell	8,532 -750	-8%	-$51.4K	0.02%	244
2019 Q2	$675K	Hold	9,282	–	–	0.02%	250
2019 Q1	$748K	Hold	9,282	–	–	0.02%	257
2018 Q4	$856K	Sell	9,282 -5,163	-36%	-$454K	0.03%	252
2018 Q3	$1.37M	Hold	14,445	–	–	0.05%	234
2018 Q2	$1.34M	Hold	14,445	–	–	0.05%	240
2018 Q1	$1.37M	Sell	14,445 -700	-5%	-$76.9K	0.05%	227
2017 Q4	$1.47M	Sell	15,145 -692	-4%	-$65.2K	0.06%	237
2017 Q3	$1.41M	Sell	15,837 -5,200	-25%	-$396K	0.06%	225
2017 Q2	$1.52M	Hold	21,037	–	–	0.07%	225
2017 Q1	$1.37M	Sell	21,037 -100	-0.5%	-$6.29K	0.07%	230
2016 Q4	$1.32M	Buy	21,137 +300	+1%	+$18.3K	0.07%	232
2016 Q3	$1.31M	Sell	20,837 -500	-2%	-$32.4K	0.07%	230
2016 Q2	$1.32M	Sell	21,337 -100	-0.5%	-$6.09K	0.08%	230
2016 Q1	$1.22M	Sell	21,437 -2,872	-12%	-$160K	0.07%	231
2015 Q4	$1.44M	Hold	24,309	–	–	0.08%	216
2015 Q3	$1.32M	Hold	24,309	–	–	0.09%	217
2015 Q2	$1.63M	Sell	24,309 -575	-2%	-$37.5K	0.09%	217
2015 Q1	$1.46M	Hold	24,884	–	–	0.08%	226
2014 Q4	$1.63M	Hold	24,884	–	–	0.1%	224
2014 Q3	$1.44M	Sell	24,884 -300	-1%	-$16.7K	0.1%	217
2014 Q2	$1.42M	Sell	25,184 -700	-3%	-$36.7K	0.1%	213
2014 Q1	$1.33M	Sell	25,884 -556	-2%	-$28.1K	0.1%	213
2013 Q4	$1.4M	Buy	26,440 +1,400	+6%	+$68.8K	0.1%	203
2013 Q3	$1.12M	Hold	25,040	–	–	0.11%	181
2013 Q2	$1.03M	Buy	+25,040	New	+$1.1M	0.1%	183

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Rice Hall James & Associates's ABBV Position: Q2 2026 in Review

Rice Hall James & Associates reduced its AbbVie (ABBV) stake by 0.19% in Q2 2026, selling an estimated $2.15K and leaving 5,199 shares worth $1.31M. The position accounts for 0.06% of the portfolio, ranked #189.

Rice Hall James & Associates first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.63M in Q2 2015. 4,206 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Rice Hall James & Associates held 5,199 shares of AbbVie worth $1.31M as of Q2 2026.
Rice Hall James & Associates sold 10 AbbVie shares in Q2 2026, an estimated $2.15K.
AbbVie made up 0.06% of Rice Hall James & Associates's portfolio in Q2 2026, its #189 holding.
Rice Hall James & Associates first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
Rice Hall James & Associates's AbbVie position peaked at $1.63M in Q2 2015.
4,206 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.